Table 7.
Putamina and Caudate Nuclei PET Percent Average Score Differences Compared with Baselines.
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | |||
|---|---|---|---|---|---|---|---|---|---|---|
| % CHANGES FROM BASELINE | 1 year | PUTAMINA | RAC | +36 | +45 | +19 | +21 | |||
| FDOPA | -12 | +5 | +7 | |||||||
| DTBZ | 0 | -27 | +15 | 5 | +50 | -22 | 0 | |||
| CAUDATE | RAC | +52 | +66 | +29 | +20 | |||||
| FDOPA | -21 | -1 | +20 | |||||||
| DTBZ | -19 | -31 | -17 | -20 | +41 | -42 | -67 | |||
| 2 years | PUTAMINA | RAC | +31 | +18 | +7 | +39 | ||||
| FDOPA | -29 | -5 | -13 | |||||||
| DTBZ | -22 | +9 | +15 | -10 | +17 | -11 | +8 | |||
| CAUDATE | RAC | +72 | +46 | +28 | +55 | |||||
| FDOPA | -34 | -10 | -65 | |||||||
| DTBZ | -131 | -48 | -40 | -12 | -71 | -33 | -51 | |||
The table reflects multidirectional changes in the uptake of the radioligands both from 1 to 2 years and from putamen to caudate in all patients. Of interest, P1 showed the best improvement in the uptake of Raclopride and no improvement in UPDRS III.
+ is improvement.
- is deterioration.
no sign is no change.